Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance
Abstract
Epigenetic dysregulation is a hallmark of cancer and contributes to tumor initiation, progression, metastasis, and therapeutic resistance. Consequently, epigenetic drugs (epidrugs) targeting DNA methylation, histone modifications, and chromatin-associated proteins have emerged as an important class of anticancer agents. Approved therapies such as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis) have demonstrated clinical benefit, particularly in hematological malignancies; however, their efficacy is often limited by off-target toxicity, acquired resistance, and incomplete target selectivity. In recent years, metallorganic compounds have gained attention as a novel generation of epigenetic modulators. The incorporation of metal centers provides unique structural, redox, and coordination properties that enable interactions with multiple epigenetic targets and facilitate the design of multifunctional agents. This review summarizes the major classes of epidrugs and discusses emerging metallorganic epigenetic therapeutics based on ruthenium, platinum, tin, copper, iridium, iron, technetium, rhenium, and gold. We examine their mechanisms of action against key epigenetic regulators, including DNMTs, HDACs, histone methyltransferases, bromodomain proteins, and chromatin-associated complexes. Particular attention is given to the potential of metal-based epidrugs to overcome therapeutic resistance through multimodal mechanisms that combine epigenetic reprogramming with modulation of DNA damage responses, oxidative stress, protein homeostasis, and chromatin organization. Although most metallorganic epidrugs remain in preclinical development, accumulating evidence suggests that they may offer advantages over conventional organic epigenetic inhibitors by enabling multi-target engagement and more durable antitumor responses. Together, these findings highlight the growing potential of metal-based epigenetic therapies and support their further development as innovative strategies for precision oncology.
Related
- Editorial: Mechanisms of drug resistance in cancer: overcoming barriers with novel pharmacological strategies
- Therapy-Induced Senescence in Cancer Treatment Resistance: Mechanisms, Evidence, and Translational Opportunities
- Overcoming the Shield: Mechanisms of Resistance to DNA Repair Inhibitors and Strategies to Restore Synthetic Lethality
- Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery
- A standardized patient-derived glioblastoma organoid platform for evaluating radiotherapy efficacy and overcoming resistance
BibTeX
@article{astapczyk2026metalbased,
title = {{Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance}},
author = {Julia Astapczyk and Olga Klaudia Szewczyk-Roszczenko and Yegor Vassetzky and Robert Czarnomysy},
journal = {Pharmacological Research},
year = {2026},
month = sep,
doi = {10.1016/j.phrs.2026.108449},
url = {https://hal.science/hal-05760274v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Metal-based epigenetic therapeutics in cancer: Mechanisms, targets, and opportunities for overcoming drug resistance
AU - Julia Astapczyk
AU - Olga Klaudia Szewczyk-Roszczenko
AU - Yegor Vassetzky
AU - Robert Czarnomysy
PY - 2026
DA - 2026/09/10
JO - Pharmacological Research
DO - 10.1016/j.phrs.2026.108449
UR - https://hal.science/hal-05760274v1
AB - Epigenetic dysregulation is a hallmark of cancer and contributes to tumor initiation, progression, metastasis, and therapeutic resistance. Consequently, epigenetic drugs (epidrugs) targeting DNA methylation, histone modifications, and chromatin-associated proteins have emerged as an important class of anticancer agents. Approved therapies such as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis) have demonstrated clinical benefit, particularly in hematological malignancies; however, their efficacy is often limited by off-target toxicity, acquired resistance, and incomplete target selectivity. In recent years, metallorganic compounds have gained attention as a novel generation of epigenetic modulators. The incorporation of metal centers provides unique structural, redox, and coordination properties that enable interactions with multiple epigenetic targets and facilitate the design of multifunctional agents. This review summarizes the major classes of epidrugs and discusses emerging metallorganic epigenetic therapeutics based on ruthenium, platinum, tin, copper, iridium, iron, technetium, rhenium, and gold. We examine their mechanisms of action against key epigenetic regulators, including DNMTs, HDACs, histone methyltransferases, bromodomain proteins, and chromatin-associated complexes. Particular attention is given to the potential of metal-based epidrugs to overcome therapeutic resistance through multimodal mechanisms that combine epigenetic reprogramming with modulation of DNA damage responses, oxidative stress, protein homeostasis, and chromatin organization. Although most metallorganic epidrugs remain in preclinical development, accumulating evidence suggests that they may offer advantages over conventional organic epigenetic inhibitors by enabling multi-target engagement and more durable antitumor responses. Together, these findings highlight the growing potential of metal-based epigenetic therapies and support their further development as innovative strategies for precision oncology.
SN - 1043-6618
SN - 1096-1186
ER -